Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annexon, Inc.

2.50
+0.0000
Post-market: 2.47-0.0300-1.20%19:56 EDT
Volume:1.33M
Turnover:3.29M
Market Cap:274.27M
PE:-2.49
High:2.52
Open:2.50
Low:2.41
Close:2.50
Loading ...

Company Profile

Company Name:
Annexon, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
100
Office Location:
1400 Sierra Point Parkway,Building C,Suite 200,Brisbane,California,United States
Zip Code:
94005
Fax:
650 636 9773
Introduction:
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Directors

Name
Position
Douglas Love
President, Chief Executive Officer and Director
William D. Young
Chairman and Director
Carol Gallagher
Director
Emmett Cunningham
Director
Jung Choi
Director
Muneer A. Satter
Director
Ricky Sun
Director
Thomas G. Wiggans
Director

Shareholders

Name
Position
Douglas Love
President, Chief Executive Officer and Director
Jennifer Lew
Executive Vice President and Chief Financial Officer
Michael Overdorf
Executive Vice President and Chief Business Officer
Sanjay Keswani
Executive Vice President and Chief Medical Officer
Ted Yednock
Executive Vice President and Chief Scientific Officer